What is the clinical evidence from this study?

Study design: Other. Population: Atrial fibrillation. Intervention: P2X7 inhibition (A-438079) and ROS scavenging (NAC). Primary outcome: Atrial fibrillation susceptibility and atrial remodeling.

What does this research mean for the field?

P2X7 antagonism reduces atrial fibrillation susceptibility, improves conduction heterogeneity, and ameliorates structural and autonomic remodeling by inhibiting the ROS-MAPK signaling axis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to elucidate the role of P2X7 receptors in atrial remodeling and susceptibility to atrial fibrillation via ROS-MAPK signaling.

May 6, 2026Journal of Cell Communication and Signaling0 citationsOpen Access

View Full Paper

P2X7 receptors promote atrial remodeling and atrial fibrillation susceptibility via reactive oxygen species‐mediated mitogen‐activated protein kinase signaling activation

LZLingnan ZhangHebei Medical University YZYeran ZhuAffiliated Hospital of Hebei University 谷谷新顺Hebei Medical University

Key Result

P2X7 antagonism reduced atrial fibrillation susceptibility, improved conduction heterogeneity, and ameliorated structural and autonomic remodeling in vivo.

Key Points

This research aims to elucidate the role of P2X7 receptors in atrial remodeling and susceptibility to atrial fibrillation via ROS-MAPK signaling.
Transcriptomic analysis of rapid-paced cardiomyocytes to assess gene expression changes.
Functional validation through P2X7 receptor activation and inhibition using A-438079.
In vivo examination of P2X7 antagonism effects on atrial fibrillation susceptibility.
P2X7 activation led to increased ROS accumulation and MAPK phosphorylation (p-ERK, p-p38, p-JNK).
Inhibition of P2X7 with A-438079 significantly reduced AF susceptibility and improved conduction.
ROS scavenging with NAC attenuated the signaling activation and action potential shortening.

Structured PICO

Does P2X7 inhibition reduce atrial fibrillation susceptibility and atrial remodeling in preclinical models?

Population

Rapid-paced cardiomyocytes and in vivo models of atrial fibrillation

Intervention

P2X7 inhibition (A-438079) and ROS scavenging (NAC)

Outcome

Atrial fibrillation susceptibility, structural and autonomic remodeling, and conduction heterogeneitysurrogate

The P2X7-ROS-MAPK signaling axis is a central mechanism in atrial fibrillation vulnerability, suggesting P2X7 inhibition as a potential therapeutic strategy.

Abstract

Atrial fibrillation (AF), the most common clinical arrhythmia, is driven by inflammatory activation and oxidative stress, though precise molecular links remain unclear. This study identifies the P2X7 receptor as a key upstream regulator orchestrating proarrhythmic atrial remodeling through reactive oxygen species (ROS)-mediated mitogen-activated protein kinase (MAPK) signaling. Transcriptomic analysis of rapid-paced cardiomyocytes revealed P2X7 upregulation and MAPK pathway enrichment. Functional validation demonstrated that P2X7 activation promotes ROS accumulation, MAPK phosphorylation (p-ERK, p-p38, and p-JNK), and pro-inflammatory cytokine release (IL-6 and IL-1β), culminating in action potential shortening and calcium handling dysfunction. Critically, both P2X7 inhibition (A-438079) and ROS scavenging (NAC) attenuated this signaling axis. In vivo, P2X7 antagonism reduced AF susceptibility, improved conduction heterogeneity, and ameliorated structural and autonomic remodeling. These results establish the P2X7-ROS-MAPK axis as a central mechanism in AF vulnerability and highlight its therapeutic potential.

Demander à l'IA

Bookmark

View Full Paper

Demander à l'IA

Bookmark

View Full Paper

P2X7 receptors promote atrial remodeling and atrial fibrillation susceptibility via reactive oxygen species‐mediated mitogen‐activated protein kinase signaling activation

Key Result

Key Points

Structured PICO

Abstract

Cite This Study

Also Consider

Also Consider